Cytosolix Inc.

Cytosolix is a platform that produces novel derivatives of known small-molecule oncology drugs. These derivatives selectively target cancer cells by targeting acidity in the tumor microenvironment, significantly improving the efficacy of treatment by reducing dose-limiting toxicities.

Based based in TOLLAND, CONNECTICUT, Cytosolix Inc. works in health.

Profile

Private US issuer recorded in the SEC Form D structured dataset for 2023Q2. Industry: Biotechnology. Revenue range: Decline to Disclose. Offering amount: 6605171.

Within the health space, the company focuses on its core offering rather than a broad product line.

Its base of operations is TOLLAND, CONNECTICUT.

Its current recorded stage is Regulation D.

Public records show total funding of about $6.6M.

Website: cytosolix.com